| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.066 | 0.06 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.06 | 0.06 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.3 | 0.07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.097 | 0.07 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.095 | 0.07 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.07 |